Rare presentations of primary melanoma and special populations: A systematic review

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 37, Issue 6, 2014, Pages 635-641

  Kottschade, Lisa A ^a   Grotz, Travis E ^a   Dronca, Roxana S ^a   Salomao, Diva R ^a   Pulido, Jose S ^a   Wasif, Nabil ^a   Jakub, James W ^a   Bagaria, Sanjay P ^a   Kumar, Riten ^b   Kaur, Judith S ^a   Morita, Shane Y ^c   Moran, Steven L ^a   Nguyen, Jesse T ^a   Nguyen, Emily C ^a   Hand, Jennifer L ^a   Erickson, Lori A ^a   Brewer, Jerry D ^a   Baum, Christian L ^a   Miller, Robert C ^a   Swanson, David L ^a   Lowe, Val ^a   Markovic, Svetomir N ^a   more..

^a MAYO CLINIC   (United States)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c UNIVERSITY OF HAWAII   (United States)

Author keywords

Familial melanoma; Malignant melanoma; Minority populations; Mucosal melanoma; Pediatric melanoma

Indexed keywords

AFRICAN AMERICAN; AMELANOTIC MELANOMA; AMERICAN INDIAN; ANORECTAL MELANOMA; ASIAN; CAUCASIAN; CHOROID MELANOMA; COLON MELANOMA; CUTANEOUS MELANOMA; DESMOPLASTIC MELANOMA; ESOPHAGUS MELANOMA; FAMILIAL MELANOMA; GASTRIC MELANOMA; HUMAN; JUVENILE MELANOMA; LATIN AMERICAN; MELANOMA; METASTATIC MELANOMA; MINORITY GROUP; PACIFIC ISLANDER; PRIMARY TUMOR; PRIMARY VAGINAL MELANOMA; REVIEW; SMALL INTESTINE MELANOMA; SUBUNGUAL MELANOMA; UVEA MELANOMA; VULVAR MELANOMA; ADULT; CHILD; ETHNOLOGY; EYE NEOPLASMS; GASTROINTESTINAL NEOPLASMS; HEAD AND NECK NEOPLASMS; MUCOSA; NAIL DISEASES; PATHOLOGY; SKIN NEOPLASMS; UROGENITAL NEOPLASMS;

ADULT; CHILD; EYE NEOPLASMS; GASTROINTESTINAL NEOPLASMS; HEAD AND NECK NEOPLASMS; HUMANS; MELANOMA; MUCOUS MEMBRANE; NAIL DISEASES; SKIN NEOPLASMS; UROGENITAL NEOPLASMS;

EID: 84916885039     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3182868e82     Document Type: Review

References (104)

1. Moreno MA, Roberts DB, Kupferman ME, et al. Mucosal melanoma of the nose and paranasal sinuses, a contemporary experience from the M. D. Anderson Cancer Center. Cancer. 2010;116:2215-2223.
2. Thariat J, Poissonnet G, Marcy PY, et al. Effect of surgical modality and hypofractionated split-course radiotherapy on local control and survival from sinonasal mucosal melanoma. Clin oncol. 2011;23:579-586.
3. Edge SB, American Joint Committee on Cancer. AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2010.
4. Seetharamu N, Ott PA, Pavlick AC. Mucosal melanomas: a casebased review of the literature. Oncologist. 2010;15:772-781.
5. Prasad ML, Patel SG, Huvos AG, et al. Primary mucosal melanoma of the head and neck: a proposal for microstaging localized, stage I (lymph node-negative) tumors. Cancer. 2004;100:1657-1664.
6. Ballantyne AJ. Malignant melanoma of the skin of the head and neck. An analysis of 405 cases. Am J Surg. 1970;120:425-431.
7. Medina JE, Ferlito A, Pellitteri PK, et al. Current management of mucosal melanoma of the head and neck. J Surg Oncol. 2003;83:116-122.
8. Meleti M, Leemans CR, de Bree R, et al. Head and neck mucosal melanoma: experience with 42 patients, with emphasis on the role of postoperative radiotherapy. Head Neck. 2008;30:1543-1551.
9. Sanchez AA, Wu TT, Prieto VG, et al. Comparison of primary and metastatic malignant melanoma of the esophagus: clinicopathologic review of 10 cases. Arch Pathol Lab Med. 2008;132: 1623-1629.
10. Lagoudianakis EE, Genetzakis M, Tsekouras DK, et al. Primary gastric melanoma: a case report. World J Gastroenterol. 2006;12:4425-4427.
11. Krausz MM, Ariel I, Behar AJ. Primary malignant melanoma of the small intestine and the APUD cell concept. J Surg Oncol. 1978;10:283-288.
12. Khalid U, Saleem T, Imam AM, et al. Pathogenesis, diagnosis and management of primary melanoma of the colon. World J Surg Oncol. 2011;9:1-9.
13. Ross M, Pezzi C, Pezzi T, et al. Patterns of failure in anorectal melanoma. A guide to surgical therapy. Arch Surg. 1990;125: 313-316.
14. Thibault C, Sagar P, Nivatvongs S, et al. Anorectal melanoma- an incurable disease? Dis Colon Rectum. 1997;40:661-668.
15. Yeh JJ, Shia J, Hwu WJ, et al. The role of abdominoperineal resection as surgical therapy for anorectal melanoma. Ann Surg. 2006;244:1012-1017.
16. Mishima Y. Melanocytic and nevocytic malignant melanomas. Cellular and subcellular differentiation. Cancer. 1967;20: 632-649.
17. Amar A, Jougon J, Edouard A, et al. Primary malignant melanoma of the small intestine. Gastroenterol Clin Biol. 1992;16: 365-367.
18. Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84, 836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1998;83:1664-1678.
19. Antonescu CR, Busam KJ, Francone TD, et al. L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. International journal of cancer. Int J Cancer. 2007;121:257-264.
20. Satzger I, Volker B, Meier A, et al. Criteria in sentinel lymph nodes of melanoma patients that predict involvement of nonsentinel lymph nodes. Ann Surg Oncol. 2008;15:1723-1732.
21. Kelly P, Zagars GK, Cormier JN, et al. Sphincter-sparing local excision and hypofractionated radiation therapy for anorectal melanoma: a 20-year experience. Cancer. 2011;117:4747-4755.
22. Nilsson PJ, Ragnarsson-Olding BK. Importance of clear resection margins in anorectal malignant melanoma. Br J Surg. 2010;97: 98-103.
23. Hu S, Parmet Y, Allen G, et al. Disparity in melanoma: a trend analysis of melanoma incidence and stage at diagnosis among whites, Hispanics, and blacks in Florida. Arch Dermatol. 2009; 145:1369-1374.
24. Piura B. Management of primary melanoma of the female urogenital tract. Lancet Oncol. 2008;9:973-981.
25. Ragnarsson-Olding BK, Nilsson BR, Kanter-Lewensohn LR, et al. Malignant melanoma of the vulva in a nationwide, 25-year study of 219 Swedish females: predictors of survival. Cancer. 1999;86:1285-1293.
26. Cohen Y, Rosenbaum E, Begum S, et al. Exon 15 BRAF mutations are uncommon in melanomas arising in nonsunexposed sites. Clin Cancer Res. 2004;10:3444-3447.
27. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363:809-819.
28. Wong CW, Fan YS, Chan TL, et al. BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs. J Clin Pathol. 2005;58:640-644.
29. Beadling C, Jacobson-Dunlop E, Hodi FS, et al. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res. 2008;14:6821-6828.
30. Curtin JA, Busam K, Pinkel D, et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006;24: 4340-4346.
31. Dhar KK, Das N, Brinkman DA, et al. Utility of sentinel node biopsy in vulvar and vaginal melanoma: report of two cases and review of the literature. Int J Gynecol Cancer. 2007;17:720-723.
32. Trifiro G, Travaini LL, Sanvito F, et al. Sentinel node detection by lymphoscintigraphy and sentinel lymph node biopsy in vulvar melanoma. Eur J Nucl Med Mol Imaging. 2010;37:736-741.
33. Singh AD, Kalyani P, Topham A. Estimating the risk of malignant transformation of a choroidal nevus. Ophthalmology. 2005;112:1784-1789.
34. Geisse LJ, Robertson DM. Iris melanomas. Am J Ophthalmol. 1985;99:638-648.
35. Conway RM, Chua WC, Qureshi C, et al. Primary iris melanoma: diagnostic features and outcome of conservative surgical treatment. Br J Ophthalmol. 2001;85:848-854.
36. Markovic SN, Erickson LA, Rao RD, et al. Malignant melanoma in the 21st century, part 2: staging, prognosis, and treatment. Mayo Clin Proc. 2007;82:490-513.
37. Diener-West M, Earle JD, Fine SL, et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS Report No. 18. Arch Ophthalmol. 2001;119:969-982.
38. Singh AD, Bergman L, Seregard S. Uveal melanoma: epidemiologic aspects. Ophthalmol Clin North Am. 2005;18:75-84, viii.
39. Singh AD, Kivela T. The collaborative ocular melanoma study. Ophthalmol Clin North Am. 2005;18:129-142, ix.
40. Onken MD, Worley LA, Ehlers JP, et al. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res. 2004;64:7205-7209.
41. Onken MD, Worley LA, Harbour JW. Association between gene expression profile, proliferation and metastasis in uveal melanoma. Curr Eye Res. 2010;35:857-863.
42. Cruz F 3rd, Rubin BP, Wilson D, et al. Absence of BRAF and NRAS mutations in uveal melanoma. Cancer Res. 2003;63: 5761-5766.
43. Van Raamsdonk CD, Bezrookove V, Green G, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature. 2009;457:599-602.
44. Wallander ML, Layfield LJ, Emerson LL, et al. KIT mutations in ocular melanoma: frequency and anatomic distribution. Mod Pathol. 2011;24:1031-1035.
45. Quinn MJ, Crotty KA, Thompson JF, et al. Desmoplastic and desmoplastic neurotropic melanoma: experience with 280 patients. Cancer. 1998;83:1128-1135.
46. Lens MB, Newton-Bishop JA, Boon AP. Desmoplastic malignant melanoma: a systematic review. Br J Dermatol. 2005;152:673-678.
47. Jaroszewski DE, Pockaj BA, DiCaudo DJ, et al. The clinical behavior of desmoplastic melanoma. Am J Surg. 2001;182: 590-595.
48. Wasif N, Gray RJ, Pockaj BA. Desmoplastic melanoma-the step-child in the melanoma family? J Surg Oncol. 2011;103: 158-162.
49. Smithers BM, McLeod GR, Little JH. Desmoplastic melanoma: patterns of recurrence. World J Surg. 1992;16:186-190.
50. Chen JY, Hruby G, Scolyer RA, et al. Desmoplastic neurotropic melanoma: a clinicopathologic analysis of 128 cases. Cancer. 2008;113:2770-2778.
51. Vongtama R, Safa A, Gallardo D, et al. Efficacy of radiation therapy in the local control of desmoplastic malignant melanoma. Head Neck. 2003;25:423-428.
52. Boyer A. Fungus hematode de petit doights. Gaz Med Paris. 1834;2:212.
53. Feibleman CE, Stoll H, Maize JC. Melanomas of the palm, sole, and nailbed: a clinicopathologic study. Cancer. 1980;46: 2492-2504.
54. Dasgupta T, Brasfield R. Subungual melanoma: 25-year review of cases. Ann Surg. 1965;161:545-552.
55. Quinn MJ, Thompson JE, Crotty K, et al. Subungual melanoma of the hand. J Hand Surg Am. 1996;21:506-511.
56. Levit EK, Kagen MH, Scher RK, et al. The ABC rule for clinical detection of subungual melanoma. J Am Acad Dermatol. 2000; 42:269-274.
57. Nguyen JT, Bakri K, Nguyen EC, et al. Surgical management of sublingual melanoma: a single institution experience of 124 cases. American Association of Plastic Surgeons Annual Meeting, Boca Raton, FL. Abstract, April 9-12, 2011.
58. Tan KB, Moncrieff M, Thompson JF, et al. Subungual melanoma: a study of 124 cases highlighting features of early lesions, potential pitfalls in diagnosis, and guidelines for histologic reporting. Am J Surg Pathol. 2007;31:1902-1912.
59. Mohrle M, Hafner HM. Is subungual melanoma related to trauma? Dermatology. 2002;204:259-261.
60. Hirai T, Fumiiri M. Ultrasonic observation of the nail matrix. Dermatol Surg. 1995;21:158-161.
61. Hutchinson J. Melanosis often not black: melanotic whitlow. Br Med J. 1886;1:491-494.
62. Krige JE, Hudson DA, Johnson CA, et al. Subungual melanoma. S Afr J Surg. 1995;33:10-14.
63. Downard CD, Rapkin LB, Gow KW. Melanoma in children and adolescents. Surg Oncol. 2007;16:215-220.
64. Lange JR, Balch CM. Melanoma in children: heightened awareness of an uncommon but often curable malignancy. Pediatrics. 2005;115:802-803.
65. Strouse JJ, Fears TR, Tucker MA, et al. Pediatric melanoma: risk factor and survival analysis of the surveillance, epidemiology and end results database. J Clin Oncol. 2005;23:4735-4741.
66. Ferrari A, Bono A, Baldi M, et al. Does melanoma behave differently in younger children than in adults? A retrospective study of 33 cases of childhood melanoma from a single institution. Pediatrics. 2005;115:649-654.
67. Jen M, Murphy M, Grant-Kels JM. Childhood melanoma. Clin Dermatol. 2009;27:529-536.
68. Spatz A, Ruiter D, Hardmeier T, et al. Melanoma in childhood: an EORTC-MCG multicenter study on the clinico-pathological aspects. Int J Cancer. 1996;68:317-324.
69. Barnhill RL, Flotte TJ, Fleischli M, et al. Cutaneous melanoma and atypical Spitz tumors in childhood. Cancer. 1995;76: 1833-1845.
70. Ludgate MW, Fullen DR, Lee J, et al. The atypical Spitz tumor of uncertain biologic potential: a series of 67 patients from a single institution. Cancer. 2009;115:631-641.
71. Mones JM, Ackerman AB. "Atypical" Spitz's nevus, "malignant" Spitz's nevus, and "metastasizing" Spitz's nevus: a critique in historical perspective of three concepts flawed fatally. Am J Dermatopathol. 2004;26:310-333.
72. Bastian BC, LeBoit PE, Pinkel D. Mutations and copy number increase of HRAS in Spitz nevi with distinctive histopathological features. Am J Pathol. 2000;157:967-972.
73. Bastian BC, Wesselmann U, Pinkel D, et al. Molecular cytogenetic analysis of Spitz nevi shows clear differences to melanoma. J Invest Dermatol. 1999;113:1065-1069.
74. Tom WL, Hsu JW, Eichenfield LF, et al. Pediatric "STUMP" lesions: evaluation and management of difficult atypical Spitzoid lesions in children. J Am Acad Dermatol. 2011;64: 559-572.
75. Richardson SK, Tannous ZS, Mihm MC Jr. Congenital and infantile melanoma: review of the literature and report of an uncommon variant, pigment-synthesizing melanoma. J Am Acad Dermatol. 2002;47:77-90.
76. Pappo AS. Melanoma in children and adolescents. Eur J Cancer. 2003;39:2651-2661.
77. Huynh PM, Grant-Kels JM, Grin CM. Childhood melanoma: update and treatment. Int J Dermatol. 2005;44:715-723.
78. Krengel S, Hauschild A, Schafer T. Melanoma risk in congenital melanocytic naevi: a systematic review. Br J Dermatol. 2006;155:1-8.
79. Ducharme EE, Silverberg NB. Pediatric malignant melanoma: an update on epidemiology, detection, and prevention. Cutis. 2009; 84:192-198.
80. Mills O, Messina JL. Pediatric melanoma: a review. Cancer Control. 2009;16:225-233.
81. Roaten JB, Partrick DA, Bensard D, et al. Survival in sentinel lymph node-positive pediatric melanoma. J Pediatr Surg. 2005;40:988-992; discussion 992.
82. Roaten JB, Partrick DA, Pearlman N, et al. Sentinel lymph node biopsy for melanoma and other melanocytic tumors in adolescents. J Pediatr Surg. 2005;40:232-235.
83. Shah NC, Gerstle JT, Stuart M, et al. Use of sentinel lymph node biopsy and high-dose interferon in pediatric patients with highrisk melanoma: the Hospital for Sick Children experience. J Pediatr Hematol Oncol. 2006;28:496-500.
84. Livestro DP, Kaine EM, Michaelson JS, et al. Melanoma in the young: differences and similarities with adult melanoma: a case-matched controlled analysis. Cancer. 2007;110: 614-624.
85. Chao MM, Schwartz JL, Wechsler DS, et al. High-risk surgically resected pediatric melanoma and adjuvant interferon therapy. Pediatr Blood Cancer. 2005;44:441-448.
86. Navid F, Furman WL, Fleming M, et al. The feasibility of adjuvant interferon alpha-2b in children with high-risk melanoma. Cancer. 2005;103:780-787.
87. Bauer M, Reaman GH, Hank JA, et al. A phase II trial of human recombinant interleukin-2 administered as a 4-day continuous infusion for children with refractory neuroblastoma, non-Hodgkin's lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma. A Childrens Cancer Group study. Cancer. 1995;75:2959-2965.
88. Osenga KL, Hank JA, Albertini MR, et al. A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group. Clin Cancer Res. 2006;12:1750-1759.
89. National Cancer Institute. Surveillance epidemiology and end result (SEER) STAT fact sheets-Melanoma of the skin. Available at: http://seer.cancer.gov/statfacts/html/melanoma.html. Accessed March 6, 2011.
90. Cress RD, Holly EA. Incidence of cutaneous melanoma among non-Hispanic whites, Hispanics, Asians, and blacks: an analysis of california cancer registry data, 1988-93. Cancer Causes Control. 1997;8:246-252.
91. Jemal A, Clegg LX, Ward E, et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer. 2004;101:3-27.
92. Zell JA, Cinar P, Mobasher M, et al. Survival for patients with invasive cutaneous melanoma among ethnic groups: the effects of socioeconomic status and treatment. J Clin Oncol. 2008; 26:66-75.
93. Johnson DS, Yamane S, Morita S, et al. Malignant melanoma in non-Caucasians: experience from Hawaii. Surg Clin North Am. 2003;83:275-282.
94. Eide MJ, Weinstock MA, Clark MA. Demographic and socioeconomic predictors of melanoma prognosis in the United States. J Health Care Poor Underserved. 2009;20:227-245.
95. Geller AC, Miller DR, Lew RA, et al. Cutaneous melanoma mortality among the socioeconomically disadvantaged in Massachusetts. Am J Public Health. 1996;86:538-543.
96. Wich LG, Ma MW, Price LS, et al. Impact of socioeconomic status and sociodemographic factors on melanoma presentation among ethnic minorities. J Community Health. 2010;36:461-468.
97. US Census Bureau News. Available at: http://www.census.gov/press-release/archives/population. Accessed February 15, 2011.
98. Leachman SA, Carucci J, Kohlmann W, et al. Selection criteria for genetic assessment of patients with familial melanoma. J Am Acad Dermatol. 2009;61:e1-e14.
99. Pho LN, Leachman SA. Genetics of pigmentation and melanoma predisposition. G Ital Dermatol Venereol. 2010;145:37-45.
100. McWilliams RR, Wieben ED, Rabe KG, et al. Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling. Eur J Hum Genet. 2011;19:472-478.
101. Christensen KD, Roberts JS, Shalowitz DI, et al. Disclosing individual CDKN2A research results to melanoma survivors: interest, impact, and demands on researchers. Cancer Epidemiol Biomarkers Prev. 2011;20:522-529.
102. Kefford R, Bishop JN, Tucker M, et al. Genetic testing for melanoma. Lancet Oncol. 2002;3:653-654.
103. Hayward NK. Genetics of melanoma predisposition. Oncogene. 2003;22:3053-3062.
104. Demenais F, Mohamdi H, Chaudru V, et al. Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study. J Natl Cancer Inst. 2010;102:1568-1583.